Article
Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report.
The Journal of international medical research - 1 Jun 2020
Cai Yangyang, Wang Yizhuo, Sun Jingnan, Wang Xu, Xu Yinghui, Sun Chao, Guo Ye, Sun Mengyao, Ma Kewei
Abstract excerpt
The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exist as compound mutations. A few reports have described the efficacy of first- and second-generation EGFR-TKIs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.